



under the aegis of
Mumbai Hematology Group



BISPECIFICS IN TREATMENT OF MYELOMA

SUNDAY,
20TH APRIL 2025

11.30 AM (IST)
(FRENCH TIME: 8.00 AM)



Speaker

Prof. Philippe Moreau

MD

Director of the SIRIC ILIAD

Prof & Head

The Hematology Department

University Hospital of Nantes

France

Supported by:



Guest Speaker



Prof. Philippe Moreau

MD
Director of the SIRIC ILIAD
Prof & Head
The Hematology Department
University Hospital of Nantes
France

Dr. Philippe Moreau is a Professor of Clinical Hematology at the University Hospital of Nantes, France

He is also the Head of the Translational Research Program in Hematology and Oncology, at the University Hospital of Nantes, France.

He has over 20 years' experience in clinical hematology and has led many pivotal clinical studies.

His interests are focused on multiple myeloma (MM) and its treatment with high-dose therapy and novel agents, including cell therapies.

He has been the Chairman of the Intergroupe Francophone du Myélome (IFM) since 2020 and Vice-President of the International Myeloma Society (IMS) since 2019.

He has been a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013.

He has served as the Principal Investigator for many international randomized phase 3 clinical trials evaluating proteasome inhibitors, Immunomodulatory drugs (IMiDs) or CD38 antibodies.

He participated in the study of Idecabtagene Vicleucel (Abecma), that received FDA approval in March 2021 as the first genetically modified autologous chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed and refractory MM.

In 2018 Professor Moreau received the Robert A. Kyle lifetime achievement award.

He is a member of the "Integrative Oncogenomics of the pathogenesis and progression of multiple myeloma" team of CRCINA, directed by Stéphane Minvielle.

He is very frequently invited speaker at international hematologic oncology meetings.

He has authored or coauthored more than 400 peer-reviewed articles that have appeared in high impact factor journals including, the NEJM, JCO, The Lancet, The Lancet Oncology, and Blood.

He is member, Editorial Board, JCO, Blood, and Blood Cancer Journal.

Chief Guest



Dr. Sudha Sethy

**Associate Professor
Dept of Clinical Hematology
SCB Medical College
Cuttack**

Scientific Agenda

Welcome note and introduction of guest speaker

Dr. M. B. Agarwal, Mumbai

Guest lecture

Subject: **Bispecifics in treatment of myeloma**

Speaker **Dr. Philippe Moreau, France**

Interactive session with Indian discussants

Moderator: **Dr. Amit Khurana, Surat**

Discussants:

- Dr. Amit Kumar, Patna
- Dr. Arijit Nag, Kolkata
- Dr. Ashok Meshram, Kolkata
- Dr. Avinash Kumar Singh, Patna
- Dr. Avinash Upadhyay, Patna
- Dr. Chandrakanth MV, Kolkata
- Dr. Debranjani Chattopadhyay, Kolkata
- Dr. Dibakar Podder, Kolkata
- Dr. Iffat Jamal, Patna
- Dr. Pankaj Malhotra, Chandigarh
- Dr. Prantar Chakrabarti, Kolkata
- Dr. Priyadarshini Peram, Bhubaneswar
- Dr. Priyanka Samal, Bhubaneswar
- Dr. Rishu Vidhatri, Patna
- Dr. Satarupa Mohapatra, Bhubaneswar
- Dr. Sisir Kumar Patra, Kolkata
- Dr. Soumya Mukherjee, Kolkata
- Dr. Subhah Chandra Jha, Patna
- Dr. Tushar Pandey, Chandigarh
- Dr. Uday Yanamandara, Pune

Vote of thanks

Dr. Amit Khurana, Surat

Registration Link

Click on below link to register:

<https://forms.gle/Gb5hsphF782Q9TPYA>

All registered delegates will receive the attendee joining link on your registered email id. You may also visit our website www.mhgindia.com

Please send your queries related to the webinar on kalpesh@perfectsquare.co.in.



under the aegis of
Mumbai Hematology Group

Hematology Centre, Ghamat Lodge,
804-A, Dr. B. Ambedkar Road,
Dadar TT, Mumbai 400014.
Email ID: mbagarwal1@gmail.com

Supported by:



Event Partner:

